Altimmune, Inc. — Director's Dealing 2022

Feb 17, 2022

SEC Form 4/A — Form 4/A

Issuer: Altimmune, Inc. (ALT)
CIK: 0001326190
Period of Report: 2022-01-25

Reporting Person: Drutz David (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-05-04	Stock Options (option to buy)	$2.40	A	139	Acquired	2022-12-31	Common Stock, par value $0.0001 (139)	Direct
2017-05-04	Stock Options (option to buy)	$17.7	A	139	Acquired	2023-12-31	Common Stock, par value $0.0001 (139)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock, par value $0.0001	17812	Direct

Footnotes

F1: The reporting person holds a stock option granted on May 4, 2017, which is exercisable for 139 shares of common stock with an exercise price of $2.40 per share and an expiration date of December 31, 2022 (the "2022 Stock Option"). The 2022 Stock Option was previously reported as covering 4,178 shares at an exercise price of $0.08 per share, but was adjusted to reflect a one-for-thirty reverse stock split that occurred on September 13, 2018. On January 26, 2022, the reporting person mistakenly filed a Form 4 reporting the exercise of the 2022 Stock Option for 70 shares of common stock. Such exercise did not occur. As of January 25, 2022, the reporting person owned only 17,812 shares of common stock and there were 139 shares of common stock unexercised and underlying the 2022 Stock Option.

F2: The reporting person holds a stock option granted on May 4, 2017 for 139 shares of common stock with an exercise price of $17.7 per share and an expiration date of December 31, 2023 (the "2023 Stock Option"). The 2023 Stock Option was previously reported as covering 4,177 shares at an exercise price of $0.59 per share, but was adjusted to reflect a one-for-thirty reverse stock split that occurred on September 13, 2018. On May 4, 2017, the reporting person mistakenly filed a Form 4 reporting that the 2023 Stock Option had an expiration date of December 31, 2022. The 2023 Stock Option has an expiration date of December 31, 2023.

F3: Pursuant to the terms of the Agreement and Plan of Merger, dated as of January 18, 2017, as amended on March 29, 2017, the Issuer assumed all outstanding options to purchase shares of Altimmune, Inc. capital stock on a 0.749106:1 basis upon closing of the merger.